Development of heterobivalent radiotracer targeting PSMA and GRPR
Oct. 21, 2022
Researchers have detailed the development and preclinical characterization of a novel heterobivalent radiotracer targeting prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPR).